Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648843 | Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg | PHASE1 | COMPLETED | 28 | — | — | Dec 1, 2002 | Jan 1, 2003 | Apr 24, 2024 | 1 | United States |
| NCT00650481 | Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg | PHASE1 | COMPLETED | 60 | — | — | Dec 1, 2002 | Jan 1, 2003 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Oxybutynin Chloride Extended-release Tablets 5 mg |
| 2 | ACTIVE_COMPARATOR | Ditropan XL® Tablets 5 mg |
| Name | Type | Description |
|---|---|---|
| Oxybutynin Chloride Extended-release Tablets 5 mg | DRUG | 4x5mg, single dose fed |
| Ditropan XL® Tablets 5 mg | DRUG | 4x5mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administra...